Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 62

Sort by

Sort Order Select

Journal Articles

Phase II Study of PD-1 Blockade Following Fludarabine/Melphalan-Based Autologous Transplantation for Acute Myeloid Leukemia Patients Ineligible for Allogeneic Transplant

Scott R. Solomon, Melhem Solh, Lawrence E. Morris, Jr., H. Kent Holland, Lizamarie Bachier-Rodriguez, Xu Zhang, Caitlin Guzowski, Katelin C Jackson, Stacey Brown, Asad Bashey

Blood (2022) 140 (Supplement 1): 1188–1189.

https://doi.org/10.1182/blood-2022-158797

Published: 2022

Journal Articles

High-Dose Bendamustine, Etoposide, Cytarabine and Melphalan (BeEAM) Conditioning Prior to Autologous Transplantation for Patients with Multiple Myeloma: Results of a Prospective Phase II Trial

Scott R. Solomon, Melhem Solh, Stacey Brown, Nancy Shegda, Katelin C Jackson, Xu Zhang, Lawrence E Morris, Asad Bashey, H. Kent Holland

Blood (2021) 138 (Supplement 1): 1831.

https://doi.org/10.1182/blood-2021-146091

Published: 2021

Journal Articles

Ixazomib Maintenance to Prevent Alloreactivity and Provide Anti-Malignancy Effects Following Nonmyeloablative T-Replete Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Scott R. Solomon, MD, Melhem Solh, MD, Stacey Brown, CCRP, Katelin C Jackson, Xu Zhang, PhD, Lawrence E Morris, MD, H. Kent Holland, MD, Asad Bashey, MD PhD

Blood (2019) 134 (Supplement_1): 1998.

https://doi.org/10.1182/blood-2019-124354

Published: 2019

Journal Articles

Selecting the Best Donor for T Cell-Replete Haploidentical Transplantation: Importance of HLA Disparity, NK Alloreactivity, and Other Clinical Variables

Scott R Solomon, MD, Michael A Aubrey, CHS, Xu Zhang, PhD, Allison Piluso, Brian M Freed, PhD DABHI, Stacey Brown, CCRP, Katelin C Jackson, Melhem M Solh, MD, Lawrence E Morris, MD, H. Kent Holland, MD, Asad Bashey, MD PhD

Blood (2017) 130 (Supplement 1): 670.

https://doi.org/10.1182/blood.V130.Suppl_1.670.670

Published: 2017

Journal Articles

Comparison of Outcomes Following Allogeneic HCT for Adverse Cytogenetic/Molecular Risk AML Using T-Replete Haploidentical Donors to Optimally Matched Related and Unrelated Donors

Asad Bashey, MD PhD, Xu Zhang, PhD, Stacey Brown, CCRP, Katelin C Jackson, Lawrence E Morris, MD, H. Kent Holland, MD, Melhem M Solh, MD, Scott R Solomon, MD

Blood (2017) 130 (Supplement 1): 4608.

https://doi.org/10.1182/blood.V130.Suppl_1.4608.4608

Published: 2017

Journal Articles

PD-1 blockade for relapsed lymphoma post–allogeneic hematopoietic cell transplant: high response rate but frequent GVHD

Blood (2017) 130 (2): 221–228.

https://doi.org/10.1182/blood-2017-01-761346

Published: 2017

Includes: Supplemental data

Journal Articles

Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation (HCT): A Single Center Analysis of 613 Adult HCT Recipients Using a Modified Composite Endpoint

Melhem Solh, MD, Lawrence E. Morris, MD, H. Kent Holland, MD, Scott R. Solomon, MD, Stacey Brown, B.A., Asad Bashey, MD PhD

Blood (2016) 128 (22): 4574.

https://doi.org/10.1182/blood.V128.22.4574.4574

Published: 2016

Journal Articles

Excellent Long Term Survival Among Patients Who Are Disease-Free at One Year after Allogeneic Hematopoietic Cell Transplantation: A Single Center Analysis of 667 Consecutive Patients

Melhem Solh, MD, Asad Bashey, MD PhD, Scott R. Solomon, MD, Lawrence E. Morris, MD, Xu Zhang, Stacey Brown, B.A., H. Kent Holland, MD

Blood (2016) 128 (22): 4622.

https://doi.org/10.1182/blood.V128.22.4622.4622

Published: 2016

Journal Articles

Myeloablative Allogeneic Hematopoietic Cell Transplantation Performed without Routine Inpatient Admission: A Single Center Experience of 462 Consecutive Patients

Asad Bashey, MD PhD, Xu Zhang, PhD, Stacey Brown, B.A., Katelin Jackson, Melhem Solh, MD, Lawrence E. Morris, MD, H. Kent Holland, MD, Scott R. Solomon, MD

Blood (2016) 128 (22): 661.

https://doi.org/10.1182/blood.V128.22.661.661

Published: 2016

Journal Articles

Checkpoint Blockade for Treatment of Relapsed Lymphoma Following Allogeneic Hematopoietic Cell Transplant: Use May be Complicated By Onset of Severe Acute Graft Versus Host Disease

Blood (2016) 128 (22): 1163.

https://doi.org/10.1182/blood.V128.22.1163.1163

Published: 2016

Journal Articles

Factors Predicting Gvhd Free, Relapse Free Survival (GRFS) after Allogeneic Hematopoietic Cell Transplantation; A Multivariable Analysis of 531 Allografts from a Single Center

Melhem Solh, MD, Xu Zhang, PhD, Katelin Connor, Stacey Brown, B.A., H. Kent Holland, MD, Lawrence E. Morris, MD, Scott R. Solomon, MD, Asad Bashey, MD PhD

Blood (2015) 126 (23): 2028.

https://doi.org/10.1182/blood.V126.23.2028.2028

Published: 2015

Journal Articles

T Cell Replete HLA- Haploidentical Donor Transplantation (HIDT) with Post-Transplant Cyclophosphamide (pTcy) Is an Effective Salvage for Patients Relapsing after a Matched Sibling or a Matched Unrelated Donor Transplantation

Melhem Solh, MD, Katelin Connor, Xu Zhang, PhD, Stacey Brown, B.A., Lawrence E. Morris, MD, H. Kent Holland, MD, Asad Bashey, MD PhD, Scott R. Solomon, MD

Blood (2015) 126 (23): 1960.

https://doi.org/10.1182/blood.V126.23.1960.1960

Published: 2015

Journal Articles

Lower Use of DLI Post Relapse of Malignancy May Result in Shorter Post-Relapse Survival (PRS) in Patients Undergoing T Cell Replete Haploidentical Donor Transplantation (HIDT) Versus Matched Related (MRD) or Matched Unrelated Donor (MUD) Hematopoietic Cell Transplantation (HCT)

Melhem Solh, MD, Xu Zhang, PhD, Stacey Brown, B.A., Lawrence E. Morris, MD, H. Kent Holland, MD, Scott R. Solomon, MD, Asad Bashey, MD PhD

Blood (2015) 126 (23): 1967.

https://doi.org/10.1182/blood.V126.23.1967.1967

Published: 2015

Journal Articles

Non-Inferior Survival of Black Versus White Patients and Superior Outcomes for Black Females Compared to Other Race/Gender Groups Following Allogeneic Transplantation for Hematologic Malignancy: A Single Center Multivariable Analysis of 475 Allografted Patients

Asad Bashey, MD PhD, Xu Zhang, PhD, Katelin Jackson, Stacey Brown, B.A., Melhem Solh, MD, Lawrence E. Morris, MD, H. Kent Holland, MD, Scott R. Solomon, MD

Blood (2015) 126 (23): 401.

https://doi.org/10.1182/blood.V126.23.401.401

Published: 2015

Journal Articles

Lineage Specific Chimerism Analysis Reveals That Mixed Donor T-Cell Chimerism Is Common in the Early Post-Transplant Period Following Myeloablative Allotransplants from HLA-Matched but Not HLA-Haploidentical Donors: A Multivariable Analysis of Allografted Patients from a Single Center

Asad Bashey, MD PhD, Xu Zhang, PhD, Katelin Jackson, Stacey Brown, B.A., Melhem Solh, MD, Lawrence E. Morris, MD, H. Kent Holland, MD, Scott R. Solomon, MD

Blood (2015) 126 (23): 4327.

https://doi.org/10.1182/blood.V126.23.4327.4327

Published: 2015

Journal Articles

Use of the Dana-Farber/CIBMTR Disease Risk Index (DRI) to Compare Outcomes of T-Replete HLA-Haploidentical Transplants Using Post-Transplant Cyclophosphamide to Matched Sibling and Matched Unrelated Donor Transplants : A Multivariate Analysis of 498 Contemporaneous Allogeneic Transplants from a Single Center

Asad Bashey, MD PhD, Xu Zhang, PhD, Stacey Brown, B.A., Katelin Connor, Lawrence E. Morris, MD, H. Kent Holland, MD, Scott R. Solomon, MD

Blood (2014) 124 (21): 1203.

https://doi.org/10.1182/blood.V124.21.1203.1203

Published: 2014

Journal Articles

TBI-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients without Matched Sibling Donors

Scott R. Solomon, MD, Connie Sizemore, PharmD, Xu Zhang, PhD, Stacey Brown, B.A., Katelin Connor, B.S., Lawrence E. Morris, MD, H. Kent Holland, MD, Asad Bashey, MD PhD

Blood (2014) 124 (21): 426.

https://doi.org/10.1182/blood.V124.21.426.426

Published: 2014

Journal Articles

Chronic GVHD Is Not Increased with the Use of PBSC Instead of Bone Marrow for T-Replete HLA-Haploidentical Transplanation Using Post-Transplant Cyclophosphamide : A Multivartiate Analysis of 116 Consecutive Transplants from a Single Center

Asad Bashey, MD PhD, Xu Zhang, PhD, Stacey Brown, B.A., Katelin Connor, Lawrence E. Morris, MD, H. Kent Holland, MD, Ridgeway Michelle, RN, Scott R. Solomon, MD

Blood (2014) 124 (21): 3922.

https://doi.org/10.1182/blood.V124.21.3922.3922

Published: 2014

Journal Articles

Corticosteroid-Free Primary Treatment of Chronic Graft-Versus-Host Disease with Rituximab Results in Excellent Responses and Rapid Time to Immunosuppression Discontinuation

Connie Sizemore, PharmD, Michelle Ridgeway, RN, OCN, Xu Zhang, PhD, Stacey Brown, B.A., Lawrence E. Morris, MD, Asad Bashey, MD PhD, H. Kent Holland, MD, Scott R. Solomon, MD

Blood (2014) 124 (21): 2487.

https://doi.org/10.1182/blood.V124.21.2487.2487

Published: 2014

Journal Articles

FLAG-Idarubicin Is Superior to Cytarabine Plus Idarubicin (7+3) for Initial Treatment of Acute Myeloid Leukemia (AML): A Multivariable Analysis of Patients Treated at a Single Center

Ronald Mihelic, PharmD, BCOP, Elizabeth Dickhaus, Pharm.D., Stacey Brown, B.A., Xu Zhang, PhD, Scott R. Solomon, MD, Lawrence E. Morris, MD, Asad Bashey, MD PhD, H. Kent Holland, MD

Blood (2014) 124 (21): 3728.

https://doi.org/10.1182/blood.V124.21.3728.3728

Published: 2014

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Phase II Study of PD-1 Blockade Following Fludarabine/Melphalan-Based Autologous Transplantation for Acute Myeloid Leukemia Patients Ineligible for Allogeneic Transplant

High-Dose Bendamustine, Etoposide, Cytarabine and Melphalan (BeEAM) Conditioning Prior to Autologous Transplantation for Patients with Multiple Myeloma: Results of a Prospective Phase II Trial

Ixazomib Maintenance to Prevent Alloreactivity and Provide Anti-Malignancy Effects Following Nonmyeloablative T-Replete Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Selecting the Best Donor for T Cell-Replete Haploidentical Transplantation: Importance of HLA Disparity, NK Alloreactivity, and Other Clinical Variables

Comparison of Outcomes Following Allogeneic HCT for Adverse Cytogenetic/Molecular Risk AML Using T-Replete Haploidentical Donors to Optimally Matched Related and Unrelated Donors

PD-1 blockade for relapsed lymphoma post–allogeneic hematopoietic cell transplant: high response rate but frequent GVHD

Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation (HCT): A Single Center Analysis of 613 Adult HCT Recipients Using a Modified Composite Endpoint

Excellent Long Term Survival Among Patients Who Are Disease-Free at One Year after Allogeneic Hematopoietic Cell Transplantation: A Single Center Analysis of 667 Consecutive Patients

Myeloablative Allogeneic Hematopoietic Cell Transplantation Performed without Routine Inpatient Admission: A Single Center Experience of 462 Consecutive Patients

Checkpoint Blockade for Treatment of Relapsed Lymphoma Following Allogeneic Hematopoietic Cell Transplant: Use May be Complicated By Onset of Severe Acute Graft Versus Host Disease

Factors Predicting Gvhd Free, Relapse Free Survival (GRFS) after Allogeneic Hematopoietic Cell Transplantation; A Multivariable Analysis of 531 Allografts from a Single Center

T Cell Replete HLA- Haploidentical Donor Transplantation (HIDT) with Post-Transplant Cyclophosphamide (pTcy) Is an Effective Salvage for Patients Relapsing after a Matched Sibling or a Matched Unrelated Donor Transplantation

Lower Use of DLI Post Relapse of Malignancy May Result in Shorter Post-Relapse Survival (PRS) in Patients Undergoing T Cell Replete Haploidentical Donor Transplantation (HIDT) Versus Matched Related (MRD) or Matched Unrelated Donor (MUD) Hematopoietic Cell Transplantation (HCT)

Non-Inferior Survival of Black Versus White Patients and Superior Outcomes for Black Females Compared to Other Race/Gender Groups Following Allogeneic Transplantation for Hematologic Malignancy: A Single Center Multivariable Analysis of 475 Allografted Patients

Lineage Specific Chimerism Analysis Reveals That Mixed Donor T-Cell Chimerism Is Common in the Early Post-Transplant Period Following Myeloablative Allotransplants from HLA-Matched but Not HLA-Haploidentical Donors: A Multivariable Analysis of Allografted Patients from a Single Center

TBI-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients without Matched Sibling Donors

Chronic GVHD Is Not Increased with the Use of PBSC Instead of Bone Marrow for T-Replete HLA-Haploidentical Transplanation Using Post-Transplant Cyclophosphamide : A Multivartiate Analysis of 116 Consecutive Transplants from a Single Center

Corticosteroid-Free Primary Treatment of Chronic Graft-Versus-Host Disease with Rituximab Results in Excellent Responses and Rapid Time to Immunosuppression Discontinuation

FLAG-Idarubicin Is Superior to Cytarabine Plus Idarubicin (7+3) for Initial Treatment of Acute Myeloid Leukemia (AML): A Multivariable Analysis of Patients Treated at a Single Center

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only